Effects of sedative psychotropic drugs combined with oxycodone on respiratory depression in the rat.

Animals Drug Therapy, Combination / adverse effects Hypnotics and Sedatives / adverse effects Oxycodone / administration & dosage Psychotropic Drugs / administration & dosage Rats Rats, Sprague-Dawley Respiratory Insufficiency / chemically induced

Journal

Clinical and translational science
ISSN: 1752-8062
Titre abrégé: Clin Transl Sci
Pays: United States
ID NLM: 101474067

Informations de publication

Date de publication:
11 2021
Historique:
revised: 05 05 2021
received: 30 03 2021
accepted: 06 05 2021
pubmed: 4 6 2021
medline: 23 2 2022
entrez: 3 6 2021
Statut: ppublish

Résumé

Following a decision to require label warnings for concurrent use of opioids and benzodiazepines and increased risk of respiratory depression and death, the US Food and Drug Administratioin (FDA) recognized that other sedative psychotropic drugs may be substituted for benzodiazepines and be used concurrently with opioids. In some cases, data on the ability of these alternatives to depress respiration alone or in conjunction with an opioid are lacking. A nonclinical in vivo model was developed that could detect worsening respiratory depression when a benzodiazepine (diazepam) was used in combination with an opioid (oxycodone) compared to the opioid alone based on an increased arterial partial pressure of carbon dioxide (pCO

Identifiants

DOI: 10.1111/cts.13080 PMID: 34080766 PMC: PMC8604244
pubmed: 34080766
doi: 10.1111/cts.13080
pmc: PMC8604244
doi:

Substances chimiques

Hypnotics and Sedatives 0
Psychotropic Drugs 0
Oxycodone CD35PMG570

Types de publication

Journal Article Research Support, U.S. Gov't, P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

2208-2219

Informations de copyright

Published 2021. This article is a U.S. Government work and is in the public domain in the USA. Clinical and Translational Science published by Wiley Periodicals LLC on behalf of the American Society for Clinical Pharmacology and Therapeutics.

Références

J Neural Transm (Vienna). 1997;104(1):97-104
pubmed: 9085197
J Neurogenet. 2011 Mar;25(1-2):52-61
pubmed: 21473737
J Pharmacol Exp Ther. 2004 Nov;311(2):576-84
pubmed: 15254142
Respir Physiol. 1999 Jan 1;115(1):1-10
pubmed: 10344410
Psychopharmacology (Berl). 2002 Feb;159(4):424-31
pubmed: 11823895
J Pharmacol Exp Ther. 2009 May;329(2):827-37
pubmed: 19244096
J Neurosci. 1992 Feb;12(2):652-63
pubmed: 1531499
Clin Pharmacol Ther. 1998 Dec;64(6):603-11
pubmed: 9871425
Expert Opin Drug Metab Toxicol. 2006 Dec;2(6):875-94
pubmed: 17125407
Drug Metab Dispos. 2004 Apr;32(4):447-54
pubmed: 15039299
Eur J Drug Metab Pharmacokinet. 1991;Spec No 3:94-101
pubmed: 1820943
Br J Clin Pharmacol. 1984 Sep;18(3):431-7
pubmed: 6487481
J Pharmacol Exp Ther. 2011 Dec;339(3):738-45
pubmed: 21875950
Pharmacoepidemiol Drug Saf. 2009 Dec;18(12):1166-75
pubmed: 19718704
Eur J Clin Pharmacol. 2010 Apr;66(4):387-97
pubmed: 20076952
Scand J Pain. 2017 Dec 29;1(1):24-33
pubmed: 29913934
Nat Med. 2007 Feb;13(2):150-5
pubmed: 17259994
J Clin Pharmacol. 2006 Feb;46(2):140-8
pubmed: 16432265
Eur J Clin Pharmacol. 2011 May;67(5):493-506
pubmed: 21140139
Br J Pharmacol. 1990 Aug;100(4):774-8
pubmed: 2207499
Innov Clin Neurosci. 2017 Aug 01;14(7-8):24-34
pubmed: 29552421
Eur J Pharmacol. 2000 Jun 16;398(2):225-38
pubmed: 10854834
Clin Drug Investig. 2012 Nov;32(11):723-7
pubmed: 23018283
Epilepsia. 2013 Aug;54(8):1444-52
pubmed: 23692553
J Clin Pharmacol. 2000 Nov;40(11):1286-95
pubmed: 11075315
Drug Discov Ther. 2010 Aug;4(4):285-97
pubmed: 22491211
Evid Based Complement Alternat Med. 2015;2015:615285
pubmed: 25793001
Clin Transl Sci. 2021 Nov;14(6):2208-2219
pubmed: 34080766
J Chromatogr B Analyt Technol Biomed Life Sci. 2019 Jun 15;1118-1119:93-100
pubmed: 31030106
Drug Metab Dispos. 2010 Mar;38(3):376-85
pubmed: 20007670
Eur J Clin Pharmacol. 2011 Jan;67(1):63-71
pubmed: 20857093
J Clin Psychiatry. 2009 Jan;70(1):122-9
pubmed: 19192473
Pharmacol Biochem Behav. 1994 Oct;49(2):281-5
pubmed: 7824539
Prog Neuropsychopharmacol Biol Psychiatry. 2000 May;24(4):521-33
pubmed: 10958148
Eur J Clin Pharmacol. 2002 Sep;58(6):423-9
pubmed: 12242602
Epilepsy Res. 1996 Jun;24(2):73-7
pubmed: 8796355
Toxicol Rep. 2020 Jan 25;7:188-197
pubmed: 32021808
J Biol Rhythms. 2005 Feb;20(1):27-37
pubmed: 15654068
Drug Metab Dispos. 2012 Jan;40(1):47-53
pubmed: 21976621
Br J Clin Pharmacol. 2010 Jul;70(1):78-87
pubmed: 20642550
Daru. 2014 Jan 07;22(1):13
pubmed: 24397986
NCHS Data Brief. 2020 Jan;(356):1-8
pubmed: 32487285
Australas Ann Med. 1967 Feb;16(1):20-32
pubmed: 6032026

Auteurs

Lin Xu (L)

Division of Applied Regulatory Science, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA.

Ashok Krishna (A)

Division of Applied Regulatory Science, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA.

Sharron Stewart (S)

Division of Applied Regulatory Science, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA.

Katherine Shea (K)

Division of Applied Regulatory Science, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA.

Rebecca Racz (R)

Division of Applied Regulatory Science, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA.

James L Weaver (JL)

Division of Applied Regulatory Science, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA.

Donna A Volpe (DA)

Division of Applied Regulatory Science, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA.

Nageswara R Pilli (NR)

Division of Applied Regulatory Science, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA.

Suresh Narayanasamy (S)

Division of Applied Regulatory Science, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA.

Jeffry Florian (J)

Division of Applied Regulatory Science, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA.

Vikram Patel (V)

Division of Applied Regulatory Science, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA.

Murali K Matta (MK)

Division of Applied Regulatory Science, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA.

Marc B Stone (MB)

Division of Psychiatry, Office of Neuroscience, Office of New Drugs, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA.

Hao Zhu (H)

Division of Pharmacometrics, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA.

Michael C Davis (MC)

Division of Psychiatry, Office of Neuroscience, Office of New Drugs, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA.
ORCID: 0000-0003-2293-5694

David G Strauss (DG)

Division of Applied Regulatory Science, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA.

Rodney Rouse (R)

Division of Applied Regulatory Science, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA.

Articles similaires

Pulmonary Atelectasis After Sedation With Propofol vs Propofol-Ketamine for Magnetic Resonance Imaging in Children: A Randomized Clinical Trial.

Yu Jeong Bang, Jeayoun Kim, Nam-Su Gil et al.
1.00
Humans Ketamine Propofol Pulmonary Atelectasis Female

Evaluating the efficacy of telesurgery with dual console SSI Mantra Surgical Robotic System: experiment on animal model and clinical trials.

Sudhir Prem Srivastava, Vishwajyoti Pascual Srivastava, Avinesh Singh et al.
1.00
Robotic Surgical Procedures Animals Humans Telemedicine Models, Animal

Odour generalisation and detection dog training.

Lyn Caldicott, Thomas W Pike, Helen E Zulch et al.
1.00
Animals Odorants Dogs Generalization, Psychological Smell

FBXO22 inhibits colitis and colorectal carcinogenesis by regulating the degradation of the S2448-phosphorylated form of mTOR.

Minle Li, Xuan Chen, Pengfei Qu et al.
1.00
Animals TOR Serine-Threonine Kinases Colorectal Neoplasms Colitis Mice

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Effects of sedative psychotropic drugs...
questionsmedicales.fr › Thérapeutique › Traitement médicamenteux › Association de médicaments › Effects of sedative psychotropic drugs...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Agents du système nerveux central › Dépresseurs du système nerveux central › Hypnotiques et sédatifs › Effects of sedative psychotropic drugs...
questionsmedicales.fr › Composés polycycliques › Hydrocarbures aromatiques polycycliques › Phénanthrènes › Morphinanes › Dérivés de la morphine › Codéine › Oxycodone › Effects of sedative psychotropic drugs...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Agents du système nerveux central › Psychoanaleptiques › Effects of sedative psychotropic drugs...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Rats › Effects of sedative psychotropic drugs...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Rats › Rat Sprague-Dawley › Effects of sedative psychotropic drugs...
questionsmedicales.fr › Maladies de l'appareil respiratoire › Troubles respiratoires › Insuffisance respiratoire › Effects of sedative psychotropic drugs...